| Oscar Gonzalo Talledo Zevallos, | |
|
1901 Encore Way, Bryant, AR 72019-8896 | |
| (501) 213-4500 | |
| Not Available |
| Full Name | Oscar Gonzalo Talledo Zevallos |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 14 Years |
| Location | 1901 Encore Way, Bryant, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265850671 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 31526 (Oklahoma) | Secondary |
| 208600000X | Surgery | MD-47408 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Arkansas Heart Hospital, Llc | Little rock, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arkansas Heart Hospital Llc | 6002838653 | 90 |
News Archive
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
A new patient resource has launched in the UK offering primary care healthcare professionals (HCPs) the opportunity to help patients self-care for their wounds and minimise scarring.
The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
Brown was diagnosed with COPD and emphysema, the third leading cause of death in the United States, only behind heart disease and cancer. Right now, the only studied interventions that prolong life for patients with severe COPD are supplemental oxygen in people with low oxygen levels and lung volume reduction surgery (LVRS) in appropriately selected individuals. Like most COPD patients, Brown was given medication but told there was no cure. He was 58 years old.
› Verified 4 days ago
| Entity Name | Arkansas Heart Hospital Rural Health Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548553811 PECOS PAC ID: 6204004815 Enrollment ID: O20110727000090 |
News Archive
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
A new patient resource has launched in the UK offering primary care healthcare professionals (HCPs) the opportunity to help patients self-care for their wounds and minimise scarring.
The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
Brown was diagnosed with COPD and emphysema, the third leading cause of death in the United States, only behind heart disease and cancer. Right now, the only studied interventions that prolong life for patients with severe COPD are supplemental oxygen in people with low oxygen levels and lung volume reduction surgery (LVRS) in appropriately selected individuals. Like most COPD patients, Brown was given medication but told there was no cure. He was 58 years old.
› Verified 4 days ago
| Entity Name | Arkansas Heart Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558653212 PECOS PAC ID: 6002838653 Enrollment ID: O20110729000327 |
News Archive
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
A new patient resource has launched in the UK offering primary care healthcare professionals (HCPs) the opportunity to help patients self-care for their wounds and minimise scarring.
The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
Brown was diagnosed with COPD and emphysema, the third leading cause of death in the United States, only behind heart disease and cancer. Right now, the only studied interventions that prolong life for patients with severe COPD are supplemental oxygen in people with low oxygen levels and lung volume reduction surgery (LVRS) in appropriately selected individuals. Like most COPD patients, Brown was given medication but told there was no cure. He was 58 years old.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Oscar Gonzalo Talledo Zevallos, 200 Hawkins Dr Dept Of, Iowa City, IA 52242-1009 Ph: () - | Oscar Gonzalo Talledo Zevallos, 1901 Encore Way, Bryant, AR 72019-8896 Ph: (501) 213-4500 |
News Archive
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
A new patient resource has launched in the UK offering primary care healthcare professionals (HCPs) the opportunity to help patients self-care for their wounds and minimise scarring.
The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
Brown was diagnosed with COPD and emphysema, the third leading cause of death in the United States, only behind heart disease and cancer. Right now, the only studied interventions that prolong life for patients with severe COPD are supplemental oxygen in people with low oxygen levels and lung volume reduction surgery (LVRS) in appropriately selected individuals. Like most COPD patients, Brown was given medication but told there was no cure. He was 58 years old.
› Verified 4 days ago